Fulgent Genetics Inc (FLGT)vsIQVIA Holdings Inc (IQV)
FLGT
Fulgent Genetics Inc
$16.67
+2.02%
HEALTHCARE · Cap: $472.83M
IQV
IQVIA Holdings Inc
$165.64
-0.27%
HEALTHCARE · Cap: $28.11B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 4955% more annual revenue ($16.31B vs $322.67M). IQV leads profitability with a 8.3% profit margin vs -18.8%. IQV appears more attractively valued with a PEG of 0.97. IQV earns a higher WallStSmart Score of 72/100 (B).
FLGT
Hold44
out of 100
Grade: D
IQV
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FLGT.
Margin of Safety
+49.1%
Fair Value
$348.46
Current Price
$165.64
$182.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Earnings expanding 23.6% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of -5.5% — below average capital efficiency
Earnings declined 98.6%
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : FLGT
The strongest argument for FLGT centers on Price/Book. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bear Case : FLGT
The primary concerns for FLGT are Market Cap, Return on Equity, EPS Growth.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Key Dynamics to Monitor
FLGT profiles as a turnaround stock while IQV is a value play — different risk/reward profiles.
IQV carries more volatility with a beta of 1.41 — expect wider price swings.
IQV is growing revenue faster at 10.3% — sustainability is the question.
IQV generates stronger free cash flow (561M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (72/100 vs 44/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fulgent Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?